ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Market reacts sharply to the newly combined company's strategic pivot from pharmaceuticals to HR technology and a new capital structure.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
H.C. Wainwright more than doubles its price target to $7.00, citing growing cost-competitiveness for the green hydrogen industry.
Agreement with White Lion Capital gives the network solutions provider the right to sell shares, securing access to growth capital.
A significant analyst price target hike for Quantum Computing Inc. (QUBT) fuels a massive rally in the leveraged ETF.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Shares surge over 76% as the company secures Nevada Tech Hub funding and a key U.S. patent for its charging technology.